ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet

Size: px

Start display at page:

Download "ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet"

Aldous Parks
5 years ago
Views:

1 (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of s National Pricing Authority ORDER New Delhi, the 2nd November, 2018 S. O. 5638(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30 th May, 2013 and S. O. 701(E) dated 10 th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; Sl. No. Name of the Formulation / Brand Name Table Strength Unit Manufacturer & Marketing Company Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Each uncoated bilayer tablet Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20 mg Metformin Hydrochloride IP 1000 mg (SR) 1 M/s Synokem s / M/s Anthem Biopharma Pvt Metformin HCL + Glimepiride (Semi Amaryl M) 3. Telmisartan + Cilnidipine + Chlorthalidone tablet Each uncoated bilayer tablet Metformin Hydrochloride IP (in prolonged release form) 500 mg Glimepiride IP 0.5 mg Chlorthalidone IP 6.25 mg Cilnidipine IP 10 mg 1 M/s Windlass Biotech Pvt. / M/s Sanofi India 1 M/s Windlass Biotech Pvt. Ltd / M/s Abbott Healthcare Pvt. Ltd Clarithromycin for Oral Suspension 5. Telmisartan + Chlorthalidone (Telmelife 3D) Each 5ml (after reconstitution) Clarithromycin IP 250mg, Titanium Dioxide IP (-). Amlodipine 5 mg Chlorthalidone IP 12.5 mg 1 ML M/s Cipla Limited M/s Akums Drugs & pharmaceuticals Ltd / M/s Neomac s Pvt. Ltd Atorvastatin + Clopidogrel Capsule 7. Amoxycillin + Potassium Clavulante Each hard gelatin capsule Atorvastatin Calcium IP eq. to Atorvastatin (As film coated tablet) 20 mg Clopidogrel (as two film coated tablet each containing 37.5mg) 75 mg Each uncoated dispersible tablet 1 Capsule M/s Windlas Biotech / M/s Abbott Healthcare Pvt. 1 M/s Saitech Medicare Pvt. / M/s Galpha

2 tablet (Clanoxy DT) 8. Tramadol + Paracetamol (Trson-P) 9. Voglibose + Metformin (Voglyson-M 0.3) 10. Rosuvastatin + Aspirin + Clopidogrel Capsules 11. Mycophenolate Mofetil Oral Suspension IP 12. Bisacodyl Suppository 13. Telmisartan + Chlorthalidone (Telmelife CH 40) 14. Cilnidipine Divalproex (Diwok OD 750 mg) 16. Clotrimazole + Beclomethasone Dipropionate Cream 17. Telmisartan + Chlorthalidone (Cresar CT) 18. Baclofen Oral Solution 19. Glimepiride + Metformin Hydrochoride 20 Glimepiride + Metformin Hydrochoride Amoxycillin Trihydrate eq. to Amoxycillin 200mg Potassium Clavulante Diluted IP eq. to Clavulanic Acid 28.5mg Tramadol Hydrochloride IP 37.5 mg Paracetamol IP 325 mg Voglibose IP 0.3 mg Metformin Hydrochloride IP 500 mg (as sustained release form) Each hard gelatin capsules Rosuvastatin Calcium IP eq. to Rosuvastatin 10 mg (as pellets) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel 75 mg (as pellets) Each 5 ml of reconstituted suspension Mycophenolate Mofetil IP 1 g, (1 bottle with 110gm powder for oral suspension containing 35gm Mycophenolate Mofetil) Each Suppository Bisacodyl IP 10 mg Chlorthalidone IP 12.5 mg Telmisartan IP 80 mg Cilnidipine 10 mg Each film coated extended release tablet Divalproex Sodium IP eq. to Valproic Acid 750 mg Cream Clotrimazole IP 1.00% Beclomethasone Dipropionate IP 0.025% Chlorthalidone IP 6.25 mg Each 5 ml Baclofen IP 5 mg Metformin Hydrochoride IP (as prolonged release) 500 mg Glimepiride IP 3 mg Metformin Hydrochoride IP (as prolonged release) 500 mg Glimepiride IP 4 mg Laboratories 1 M/s Unison s Pvt. 1 M/s Unison s Pvt. 1 Capsule M/s Synokem s / M/s Intas s M/s Panacea Biotec M/s Meridian Enterprises Suppository Pvt. 1 M/s Akum Drugs & s / M/s Neomac s Pvt. 1 M/s Pure and Cure Healthcare Pvt. / M/s Abbott Healthcare Pvt. 1 M/s Swiss Garnier Biotech / M/s Wockhardt 1 GM M/s Curetech Skincare / M/s Mankind Pharma 1 M/s Acme Formulations Pvt. / M/s Cipla 1 ML Industries / Pharma Laboratories 1 Pharma Laboratories 1 Pharma Laboratories

3 21. Glimepiride + Metformin Hydrochoride 22. Metformin HCL + Gliclazide + Pioglitazone s 23. Metformin HCL + Gliclazide + Pioglitazone s 24. Chlorthalidone + (Telsar CH 40/6.25) 25. Chlorthalidone + (Telsar CH 40/12.5) 26. Chlorthalidone + (Telsar CH 80/12.5) 27. Divalproex (Diwok OD 250 mg) 28. Voglibose + Metformin tablet 29. Amoxycillin + Potassium Clavulnate Dry Syrup (Blumox-CA Forte) 30. Rosuvastatin + Aspirin + Clopidogrel Capsule 31. Rosuvastatin + Aspirin + Clopidogrel Metformin Hydrochoride IP (as prolonged release) 1000mg Glimepiride IP 4 mg Metformin Hydrochoride IP (sustained release) 500 mg Gliclazide IP (sustained release) 30 mg Pioglitazone HCL eq. to Pioglitazone 15 mg Metformin Hydrochoride IP (sustained release) 500 mg Gliclazide IP (sustained release) 60 mg Pioglitazone HCL eq. to Pioglitazone 15 mg Chlorthalidone IP 6.25 mg Chlorthalidone IP 12.5mg Chlorthalidone IP 12.5mg Telmisartan IP 80 mg Each film coated extended release tablet Divalproex Sodium IP eq. to Valproic Acid 250 mg Each uncoated tablet Voglibose IP 0.2 mg Metformin HCL IP 500 mg Each combipack containing: a) Amoxycillin and Potassium Clavulanate Oral Suspension IP Each 5 ml suspension containing Amoxycillin Trihydrate IP eq. to Amoxycillin 400 mg Potassium Clavulnate diluted IP eq. to Clavulanic Acid 57 mg b) 1 vial sterile water for injection IP Each vial containing Sterile water for injection IP 30 ml Each hard gelatin capsule Rosuvastatin Calcium IP eq. to Rosuvastatin 20 mg (as pellets) Aspirin IP 75 mg (as enteric coated pellets) Clopidogrel 75 mg (as pellets) Each hard gelatin capsule Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as pellets) 1 Pharma Laboratories 1 M/s Eris Lifesciences 1 M/s Eris Lifesciences 1 M/s Gkm New Pharma / M/s Torrent s 1 M/s Gkm New Pharma / M/s Torrent s 1 M/s Gkm New Pharma / M/s Torrent s 1 M/s Swiss Garnier Biotech / M/s Wockhardt 1 M/s Eris Lifesciences 1 ML M/s Akums Drugs & s / M/s Blue Cross Laboratories Pvt. 1 Capsule M/s Synokem s / M/s Emcure s 1 Capsule M/s Synokem s / M/s Emcure

4 Capsule 32. Diclofenac + Virgin Linseed Oil + Methyl Salicylate + Menthol + Capsaicin Gel (Diclofam Hot) 33. Clotrimazole + Lignocaine Ear Drops (Triben) 34. Timolol + Brinzolamide Eye Drops 35. Diclofenac + Methyl 36. Diclofenac + Methyl 37. Olmesartan + Chlorthalidone (TRIOLSAR 20) 38. Olmesartan + Chlorthalidone (TRIOLSAR 40) Aspirin IP 75mg (as enteric coated pellets) Clopidogrel 75mg (as pellets) Gel containing Diclofenac Diethylamine BP 1.16% (eq. to Diclofenac Sodium 1% ) Virgin linseed Oil BP 3% (containing predominantly Alpha Linolenic Acid) Methyl Salicylate IP 10% Menthol IP 5% Capsaicin USP , Benzyl Alcohol IP 1% Ear drops Clotrimazole IP 1.0% w/v Lignocaine Hydrochloride IP 2.0% w/v Each ml contains Brinzolamide IP 1.0 w/v Timolol Maleate IP eq. to Timolol 0.5% w/v, Benzalkonium Chloride IP 0.01% w/v (as preservative) Methyl Salcylate IP 10% & Menthol IP 5% Methyl Salcylate IP 10% & Menthol IP 5% Olmesartan Medoxomil 20mg, Chlorthalidone IP 6.25mg, Olmesartan Medoxomil 40mg, Chlorthalidone IP 6.25mg, s 1 GM M/s Akums Drugs & s / M/s Abbott Healthcare Pvt. 1 ML M/s Akums Drugs & s / M/s Jenburkt s 5ML M/s Ajanta Pharma (20 gram) (30 gram) Industries Industries / M/s Unichem / M/s Unichem

5 39. Losartan + Chlorthalidone + Amlodipine (TRILOSAR 6.25 ) 40. Losartan + Chlorthalidone + Amlodipine (TRILOSAR 12.50) 41. Darunavir + Ritonavir tablet Losartan Potassium IP 50mg, Chlorthalidone IP 6.25mg, Losartan Potassium IP 50mg, Chlorthalidone IP 12.50mg, Darunavir Ethanolate eq. to Darunavir 600mg and Ritonavir IP 100mg tablet / M/s Unichem / M/s Unichem 1 M/s Emcure s Limited Telmisartan + Chlorthalidone (Tazloc AC 12.5) 43. Darunavir + Ritonavir tablet (Durart R 450) 44. Diclofenac + Methyl + Menthol Salicylate + Menthol + Turpentine Oil Gel (Diclotal MR Gel) 45. Lamivudine + Tenofovir + Dolugetravir tablet 46. Darunavir + Ritonavir tablet (Danavir R) 47. Lamivudine + Tenofovir + Dolugetravir tablet (ACRIPTEGA) Amlodipine 5 mg Chlorthalidone IP 12.5 mg Each film coated tablet Darunavir 400mg & Ritonavir 50mg s Diclofenac Diethylamine BP 1.16% (eq. to Diclofenac Sodium 1%), Methyl Salicylate IP 5%, Mephenesin IP 85 5%, Menthol IP 2%, Turpentine Oil BP 3% Lamivudine IP 300mg, Tenofovir Disoproxil Fumarate IP 300mg eq. to Tenofovir Disoproxil 245mg, Dolugetravir Sodium eq. to Dolutegravir 50mg. Darunavir Ethanolate eq. to Darunavir 800mg, Ritonavir 100mg Each uncoated tablet Lamivudine IP 300mg, Tenofovir Disoproxil Fumarate IP 300mg, Dolugetravir Sodium eq. to Dolutegravir 50mg. 1 M/s Aeon Formulations Pvt. / M/s USV Pvt. 1 M/s Mylan Laboratories Pvt. / M/s Mylan s Pvt. 1 GM M/s The Madras s / M/s Blue Cross Laboratories Pvt. 1 M/s Emcure s Limited 1 M/s Hetero Labs Limited / M/s Hetero Healthcare Limited 1 M/s Mylan / M/s Mylan s Private Limited

6 48. Daclatasvir + Sofosbuvir tablet (HEPCINAT PLUS) 49. Daclatasvir + Sofosbuvir tablet 50. Daclatasvir + Sofosbuvir tablet (MYHEP DVIR) 51. Diclofenac + Methyl 52. Diclofenac + Methyl 53. Ceftriaxone 1 gm plus Tazobactum 125 mg injection 54. Cefpodoxime + Potassium Dry Syrup (Cefoprox CV) 55. Cefpodoxime + Potassium Dry Syrup (Cefoprox CV) Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg Daclatasvir Dihydrochloride eq. to Daclatasvir 60mg, Sofosbuvir 400mg Methyl Salicylate IP 10% & Menthol IP 5% Methyl Salcylate IP 10% & Menthol IP 5% Each injection vial Ceftriaxone Sodium IP eq. to Ceftriaxone 1 gm Tazobactum Sodium eq. to Tazobactum 125 mg Each 5 ml of the reconstituted suspension Cefpodoxime Proxetil IP eq. to Cefpodoxime 50 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid mg Each 5 ml of the reconstituted suspension Cefpodoxime Proxetil IP eq. to Cefpodoxime 100 mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 62.5mg 1 M/s Natco Pharma Limited 1 M/s Natco Pharma Limited / M/s Cadila Healthcare Limited 1 M/s Mylan Laboratories Pvt. / M/s Mylan s Pvt. (15 gram) (10 gram) Industries Industries 1 Vial M/s Innova Captab Pvt. / M/s Emcure s Ltd 1 ML M/s Hetero Labs Ltd / M/s Cipla Limited 1 ML M/s Hetero Labs Ltd / M/s Cipla Limited Note: (a) The manufacturer of above mentioned formulations i.e. new drug under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

7 (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, The manufacturer shall issue a price list in Form V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, (g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. PN/192/60/2018/F F. No. 8(60)/2018/D.P./NPPA-Div.-II (BALJIT SINGH) Assistant Director

ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet

ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet (Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority